Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Response (DDR) and Synthetic Lethality Pathway Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BRCA1 drug discovery and synthetic lethality screening. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRCA1 Recombinant Proteins (Functional Domains: RING, BRCT) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed for native post-translational modifications. Suitable for protein-protein interaction (PPI) assays. |
View BRCA1 Products |
| Gene Delivery | BRCA1 Promise-ORF / Lentivirus Full-length WT or clinical mutant (e.g., C61G, 185delAG) ORF lentiviral particles for stable cell line construction and functional rescue assays. |
View BRCA1 Products |
| Benchmark Ab | Anti-BRCA1 Recombinant Antibody Recombinant positive control antibody for Western Blot, Immunofluorescence, and Flow Cytometry validation. |
View BRCA1 Products |
| Validator | BRCA1 siRNA Set Validated siRNA pool for transient knockdown to establish BRCA1-deficient phenotypes in vitro. |
View BRCA1 Products |
| Related Target A | PARP1 The primary synthetic lethality partner. Essential for screening PARP inhibitors (PARPi) in BRCA1-deficient backgrounds. |
View PARP1 Products |
| Related Target B | POLQ (DNA Polymerase Theta) Emerging synthetic lethality target. POLQ inhibition selectively kills BRCA1/2-deficient tumor cells while sparing normal tissues. |
View POLQ Products |
| Related Target C | ATR Key kinase in the replication stress response; ATR inhibitors synergize strongly with BRCA1 deficiency or PARP inhibition. |
View ATR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting unstable multidomain nuclear proteins | Domain-specific recombinant designs (RING/BRCT) optimized for structural stability and solubility. |
| Generating robust BRCA1-deficient screening models | Sequence-verified Lentivirus delivering specific clinical mutants or shRNA to establish stable disease-relevant cell lines. |
| Lack of Controls | Sequence-verified recombinant benchmark antibodies included for assay standardization. |
| Off-target siRNA effects | Multi-sequence pooled siRNA sets validated for target-specific transcript knockdown. |
Live BRCA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape surrounding BRCA1 is undergoing a major evolution. While BRCA1 itself is an intracellular tumor suppressor and generally considered "undruggable" by direct small-molecule inhibitors or monoclonal antibodies, it serves as the ultimate biomarker and driver for Synthetic Lethality therapeutics. The clinic is currently dominated by PARP inhibitors (PARPi), but emerging clinical pipelines are rapidly shifting toward next-generation DDR targets to overcome PARPi resistance.
The next wave of R&D focuses on exploiting alternative repair pathways that become essential in BRCA1-deficient cells. Therapies targeting POLQ (Polymerase Theta), USP1, ATR, and WEE1 are actively entering clinical trials, aiming to bypass homologous recombination deficiencies (HRD) and restore therapeutic efficacy in BRCA-mutant ovarian, breast, and prostate cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PARP1 Selective) | AstraZeneca, GSK, Pfizer | Ovarian Cancer, gBRCA+ Breast Cancer, Prostate Cancer | Synthetic lethality screening (Requires high-efficiency BRCA1 Lentiviral knockdown or mutant cell lines). |
| Small Molecule (POLQ Inhibitors) | Repare Therapeutics, Artios Pharma | BRCA1/2-deficient Solid Tumors (PARPi-resistant) | Co-isogenic cell line validation (Requires stable expression of BRCA1 WT vs mutant variants via Lentivirus). |
| Gene Therapy / mRNA | Academic Institutions, Biotech Startups | BRCA-deficient Malignancies | Functional rescue assays (Requires highly pure, sequence-verified BRCA1 recombinant proteins to validate expression/activity). |